Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olvimulogene nanivacirepvec - Genelux Corporation

Drug Profile

Olvimulogene nanivacirepvec - Genelux Corporation

Alternative Names: GL-ONC1; GLV-1h68; Olvi-Vec - Genelux Corporation

Latest Information Update: 29 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genelux Corporation
  • Developer Genelux Corporation; Memorial Sloan-Kettering Cancer Center; Newsoara Biopharma
  • Class Antineoplastics; Diagnostic agents; Imaging agents; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Cell death stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase I/II Non-small cell lung cancer; Small cell lung cancer
  • No development reported Head and neck cancer; Malignant pleural effusion; Solid tumours

Most Recent Events

  • 27 Nov 2023 Olvimulogene nanivacirepvec - Genelux Corporation receives Fast Track designation for Ovarian cancer [Intraperitoneal,Infusion] (Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in USA
  • 14 Nov 2023 Phase-I/II clinical trials in Small cell lung cancer (IV) before November 2023
  • 14 Aug 2023 Phase-I/II clinical trials in Non-small cell lung cancer in China (IV), prior to August 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top